

Index

- Acetaminophen, 61–62
Acinetobacter baumannii, 140
 Acquired immunodeficiency syndrome (AIDS), 102
 Actinomycosis, 160
 Activated protein C
 in severe sepsis, 247
 Acute bronchitis, 185
 Acute diskitis, 159–160
 Acute disseminated encephalomyelitis (ADEM),
 146–147
 Acute gastroenteritis, 74–82
 antibiotics and, 79–80
 antiemetics in, 80
 dehydration in, 74–75
 diet in, 80–81
 breast-feeding, 80
 soy fiber in, 81
 vitamin A in, 81
 zinc in, 81
 management guidelines, 82
 nitazoxanide in, 82
 ORS in, 78
 probiotics in, 81–82
 rehydration in, 75–77
 calculations of, 76*b*
 IV fluids for, 79
 Acute laryngotracheobronchitis, 180–181
 Acute osteomyelitis, 156–159
 antibiotic therapy in, 158–159
 delivery mode in, 159
 duration of, 159
 bone scan in, 157
 clinical features of, 156
 CT scans, 157
 diagnosis of, 156–157
 imaging in, 156–157
 laboratory tests in, 156–157
 MRI in, 157
 organisms in, 157–158
 Acute otitis media (AOM), 166–169
 antibiotics for, 167–169
 diagnosis of, 166
 organisms in, 166–167
 recurrent, 169
 treatment of, 167–169
 Acute phase reactants, 59–60
 Acute rheumatic fever, 22–26
 antibiotic prophylaxis of, 25–26
 diagnosis of, 24
 prevention of, 24–25
 treatment of, 25
 Acute tonsillitis, 176–180
 Acyclovir, 44, 145, 186, 218, 286, 287, 290, 291,
 294
 ADEM. *See* Acute disseminated encephalomyelitis
 Adenovirus, 43
 ADH. *See* Antidiuretic hormone
 Agropyron caninum, 229
 AIDS. *See* Acquired immunodeficiency syndrome
 Albendazole, 95, 230, 257
 Algorithms
 bacterial meningitis management, 135*f*
 febrile child management, 58*f*
 Amebiasis, 88–89
 Amebic dysentery, 88–89
 Amebic liver abscess, 89
 American Medical Association, 21
 Amikacin, 50
 Aminoglycosides, 17, 21, 119, 159, 171–172, 275
 Amoxicillin, 12, 40, 41, 134, 168–169, 169, 175, 176, 187, 189,
 193, 219, 225, 237, 238, 243, 275
 Amoxicillin-clavulanate, 10, 12, 158, 162, 170
 Amphotericin, 20, 50, 123, 149, 192–193
 Amphotericin B, 122
 Ampicillin, 134, 219, 225
Ancylostoma braziliense, 229
Ancylostoma duodenale, 95, 229
 Anthrax, 226

Index

- Antibiotics, 60–61, 146. *See also specific types*
 broad-spectrum, 9–10, 11–12
 bronchiectasis, 195
 cystic fibrosis, 197
 diarrhea associated with, 82–83
 dose and duration, 10, 12
 febrile neutropenia and, 118–120
 for AOM, 167–169
 for bacterial meningitis, 134–137, 138*t*
 for bites, 224–225
 for bronchiectasis, 195
 for bronchiolitis, 184
 for common cold, 173–174
 for community-acquired pneumonia, 186–187
 for cystic fibrosis, 195–196
 for cystitis, 275
 for GAS, 177–178
 for necrotizing skin infections, 232–233
 for OME, 170
 for pyelonephritis, 275–276
 for severe sepsis, 243–244
 for sore throat, 177
 for UTIs, 278–279
 in acute gastroenteritis, 79–80
 in acute osteomyelitis, 158–159
 in cellulitis, 229
 in cervical lymphadenopathy, 33
 in erysipelas, 229
 in fever management, 60–61
 intermittent catheterization and, 280
 measles and, 288–289
 mucosal penetration, 11
 multiple, 12
 narrow-spectrum, 9–10, 11–12
 oral, 12
 parenteral, 12
 population use of, 10
 prehospital treatment of, 249–250
 prevention, 12
 reducing use of, 11
 resistance, 9–12
 single, 12
 topical, 10–11, 12
- Antidiuretic hormone (ADH), 79
- Antiemetics, in acute gastroenteritis, 80
- Antifungals, 121, 122, 123
- Antihistamines, 169
 common cold and, 174
 for chronic OME, 171
- Antimicrobials, 12, 16, 33, 51, 67, 148
- Antipyretics, in fever management, 61–62
- AOM. *See* Acute otitis media
- Artemether, 259
- Artesunate, 260
- Arthritis, 162
- Aspergillus*, 142, 191
 allergic bronchopulmonary, 191
 invasive pulmonary, 191–192
- Aspirin, 25, 65–66
- Asplenia, 125–126
 antibiotic prophylaxis for, 126
 immunization for, 126
 reducing risk of, 127*t*
- Atovaquone-proguanil, 264
- Azithromycin, 25, 34, 48, 67, 83, 84, 86, 88, 178, 182, 186, 187, 203, 213, 217, 219, 220
- Bacillus anthracis*, 226–228
- Bacitracin, 43, 44, 45, 47, 49
- Bacterial meningitis, 132–141
 algorithms for management of, 135*f*
 antibiotics for, 134–137
 aseptic, 144
 chemoprophylaxis, 138–139
 clinical diagnosis of, 132
 cochlear implants, 140
 corticosteroids for, 137–138
 IV fluids for, 138
 recurrent, 140
 skull fracture and, 139–140
 treatment of, 134–138
 in neonates, 134–136
- Bacterial vaginosis, 214
- Balanitis, 211
- Balanoposthitis, 211
- Bartonella*, 20, 66–67, 157
- BCG vaccine, 199
- Benzathine penicillin, 26, 178, 179, 217, 231
- Benzyl benzoate, 235
- Benzylpenicillin, 17, 35, 36, 37, 60, 61, 142, 143, 147, 186, 187, 189, 193, 217, 249*t*, 250, 252
 streptococci-resistance to, 18
- Beta-lactam, 10, 119
- Bilharziasis, 265–266
- Bites, 224–226
 immunization and, 225–226
 prophylactic antibiotics for, 224–225
- Blastocystis*, 82, 89
- Blepharokeratoconjunctivitis, 48
- Blood cultures, 15, 20, 49, 63, 124, 142, 156, 196
- Boils, 226–228
- Bordetella parapertussis*, 181
- Bordetella pertussis*, 181
- Borrelia burgdorferi*, 67–68, 147
- Brain abscesses, 142–143
- Brazilian purpuric fever, 43

- Breast-feeding
 gastroenteritis and, 80
 in TB, 202
 MTCT and, 110–111
- Bronchiectasis, 195
 antibiotics for, 195
 physical therapy for, 195
- Bronchiolitis, 182–185
 antibiotics for, 184
 bronchodilators for, 183
 chest physiotherapy for, 184
 corticosteroids for, 183–184
 epinephrine for, 183
 palivizumab, 184–185
 ribavirin for, 183
 RSV immunoglobulin, 184
 surfactant for, 184
 treatment of, 183–184
- Bronchodilators
 for bronchiolitis, 183
- Brucellosis, 256
- Budesonide, 180
- Burkholderia cepacia*, 197
- Burkholderia pseudomallei*, 264
- C-reactive protein (CRP), 156, 159
- Caesarean section, 110
- Campylobacter enteritis*, 83
- Campylobacter jejuni*, 150
- Candida*, 15, 20, 47, 123, 192, 211
- Candidosis, 123
- Carbuncles, 226–228
- Cardiac infections, 14–25
- Case-control studies, 3
- Cat scratch disease, 34, 66–67
- Catheter-associated bacteriuria, 279–280
- Catheter-associated candiduria, 279
- Cefazolin, 40, 41, 49
- Cefdinir, 170, 179, 187
- Cefepime, 190
- Cefixime, 213, 215, 275
- Cefotaxime, 14, 36, 40, 41, 45, 61, 134, 136, 142, 147, 172, 184, 186, 189, 194, 213, 215, 225, 226, 236, 243, 244, 250
- Cefotetan, 219
- Cefpodoxime, 168, 170, 176, 178–179, 187
- Ceftazidime, 50, 119, 141, 142, 158
- Ceftriaxone, 17, 40, 41, 45, 61, 68, 86, 136, 139, 142, 143, 147, 189, 213, 215, 220, 225, 250, 251, 264
- Cefuroxime, 40, 170, 176, 178, 186, 187, 188, 189
- Cellulitis, 228–229. *See* Periocular cellulitis
 antibiotic treatment of, 229
 perianal, 233–234
- Cephalexin, 33, 40, 49, 158, 178, 215, 228, 231, 275
- Cephalothin, 162, 188, 229, 234, 237, 238, 244, 252
- Cephazolin, 162, 188, 229, 234, 237, 238, 244, 252
- Cerebrospinal fluid (CSF), 60
 glucose, 134
 lactate, 134
 microscopy, 144
 organisms in, 134
 PCR testing, 144–145
 pleocytosis, 144*b*
 protein, 134
 rapid bacterial assays on, 134
 white count, 134
- Cervical infections, 29–37
- Cervical intraepithelial neoplasia (CIN), 218
- Cervical lymphadenopathy, 29–34
 acute presentation of, 29–30
 bilateral, 30
 causes of, 29, 30*t*
 chronic presentation of, 29–30
 examination of, 31–32
 fine needle aspiration in, 32, 33
 hematology in, 32
 history, 29–31
 age, 31
 cat contact, 30–31
 dental infections, 31
 exposure, 31
 investigation of, 32
 neck swelling in, 30
 PCR in, 33
 treatment of, 33–34
 antibiotic, 33
 cat scratch disease, 34
 daily regimen, 34
 for atypical mycobacterial infections, 34
 surgical, 33
 tuberculin skin testing in, 32–33
 unilateral, 30
- Cervicofacial actinomycosis, 35
- CGD. *See* Chronic granulomatous disease
- Chalazion, 48–49
- Chemoprophylaxis
 in bacterial meningitis, 138–139
 in infective endocarditis, 21–22, 23*t*
- Chest physiotherapy, for bronchiolitis, 184
- Chest radiography, 60, 147, 257
- Chicken pox, 290
- Chlamydia*, 181, 213
- Chloramphenicol, 45
- Chloroquine, 259, 261, 264
 resistance to, 263–264
- Cholera, 83–84

Index

- Chorioretinitis, 50
 cytomegalovirus, 50–51
 toxoplasma, 51
- Chronic bronchitis, 185
- Chronic dacryocystitis, 47
- Chronic granulomatous disease (CGD), 227
- Chronic osteomyelitis, 160
- Chronic recurrent multifocal osteomyelitis (CRMO), 160–161
- Chronic renal damage, 277–278
- Chronic suppurative otitis media (CSOM), 171–172
- Cilastatin, 190
- CIN. *See* Cervical intraepithelial neoplasia
- Ciprofloxacin, 11, 45, 48, 50, 83, 84, 86, 88, 137, 139, 158, 162, 172, 196, 225, 226, 236, 244, 250, 251
- Clarithromycin, 34, 182, 186, 187, 203, 237, 265
- Clavulanate, 162, 173, 176, 189, 225, 238
- Clindamycin, 10, 33, 36, 37, 40, 41, 51, 91, 158, 162, 188, 193, 225, 227, 228, 229, 231, 232, 234, 238, 244, 252
- Clinical Evidence, 2
- Clostridium difficile*, 11, 82
- Clostridium perfringens*, 231
- Clotrimazole, 214
- CNS shunt infections, 140–141
- Cochlear implants, bacterial meningitis and, 140
- Cochrane Collaboration, 1–2
- Cochrane Library, 1–2, 4f
- Cochrane reviews, 2, 3–5, 21, 25, 43
- Cochrane, Archie, 1
- Cohort studies, 2–3
- Colony-stimulating factors
 febrile neutropenia and, 124–125
 in severe sepsis, 247
- Common cold, 173–175
 antibiotics for, 173–174
 antihistamines and, 174
 decongestants and, 174
 vitamin C and, 174
 zinc and, 174–175
- Computed tomography (CT), 232
 in acute osteomyelitis, 156–157
 in hepatic hydatid cysts, 257
 in mastoiditis, 172–173
 in recurrent bacterial meningitis, 140
- Conjunctivitis, 41–45
 acute hemorrhagic, 42
 chemical, 45
 chlamydia, 46
 chronic, 47–48
 clinical features of, 42–43
 from *S. aureus*, 46–47
 gonococcal, 42
- HSV, 42
 neonatal, 46
 meningococcal, 42
 organisms causing, 41–42
 treatment of, 43–45
 bacterial, 44–45
 gonococcal, 45
 HSV, 44
 meningococcal, 45
 viral, 44
- Conjunctivitis-otitis syndrome, 42
- Corticosteroids, 25, 146
 for bacterial meningitis, 137–138
 for bronchiolitis, 183–184
 for OME, 170
 for PCP, 191
 in KD, 65–66
 in meningococcal infection, 250–251
 in septic shock, 246
 TB and, 202
- Corynebacterium diphtheriae*, 20
- CRMO. *See* Chronic recurrent multifocal osteomyelitis
- Crotamiton, 235
- Croup, 180–181
- CRP. *See* C-reactive protein
- Cryptococcal meningitis, 149
- Cryptococcus neoformans*
 pneumonia, 192–193
- Cryptosporidium*, 82, 89–90, 102
- CSF. *See* Cerebrospinal fluid
- CSOM. *See* Chronic suppurative otitis media
- CT. *See* Computed tomography
- Cutaneous larva migrans, 229–230
- Cyclic neutropenia, 70
- Cystic fibrosis, 195–196
 elective admission for, 196–197
 hypertonic saline for, 198
 nebulized antibiotics for, 197
 physical therapy for, 198
 rhDNase for, 198
- Cystitis, 273–274
 antibiotic treatment for, 275
- Cytokines, 251
- Cytomegalovirus, 283–284
 opportunistic, 284t
- Cytomegalovirus chorioretinitis, 50–51
- Dacryoadenitis, 49
- Dacryocystitis, 49
- Decongestants, 169
 common cold and, 174
 for chronic OME, 171
- Deep neck infections, 35–36
 clinical features of, 35t

- Dehydration
 in acute gastroenteritis, 74–75
 replacement fluids, 76*b*
 severe, 77
- Dental infections
 in cervical lymphadenopathy, 31
- Dexamethasone, 137, 156, 162, 172, 173, 180
- Di/fluclo/oxa/nafcillin, 17, 19, 21, 33, 40, 41, 49, 61, 143,
 158, 162, 187, 188, 227, 229, 231, 234, 237, 238, 243,
 252
- Diagnosis
 evidence about, 3
 searching for queries about, 7–8
- Diarrhea
 antibiotic-associated, 82–83
 traveler's, 86–88
- Diet
 in acute gastroenteritis, 80–81
- Dihydroartemisinin-piperaquine, 259
- Diloxanide furoate, 89
- Dimercaptosuccinic acid (DMSA), 274, 277
- Directly observed therapy (DOT), 201
 TB, 202
- DMSA. *See* Dimercaptosuccinic acid
- DOT. *See* Directly observed therapy
- Doxycycline, 19, 68, 84, 215, 219, 256, 259, 264, 265
- EBM. *See* Evidence-based medicine
- EBV. *See* Epstein-Barr virus
- Echinococcus granulosus*, 95, 257
- Echocardiography, 16*b*
 in infective endocarditis, 15
 in KD, 64
- ECMO. *See* Extracorporeal membrane oxygenation
- Eczema herpeticum, 287
- EHEC enteritis. *See* Enterohemorrhagic *E. coli* enteritis
- EIA. *See* Enzyme immunoassay
- Endophthalmitis, 49–50
- Entamoeba*, 82, 88–89
- Enterobius, 212
- Enterobius vermicularis*, 95
- Enterococcus faecalis*, 18, 140
- Enterococcus faecium*, 18
- Enterohemorrhagic *E. coli* (EHEC) enteritis, 84
- Enteropathogenic *E. coli* (EPEC) enteritis, 84
- Enterotoxigenic *E. coli* (ETEC), 87
- Enzyme immunoassay (EIA), 67
- EPEC enteritis. *See* Enteropathogenic *E. coli* enteritis
- Epididymo-orchitis, 214–215
- Epinephrine, 180
 for bronchiolitis, 183
- Epstein-Barr virus (EBV), 284–285
- Erysipelas, 229, 232
- Erythromycin, 10, 26, 46, 83, 84, 182, 186
- ESBL. *See* Extended spectrum betalactamase
- Escherichia coli*, 10, 49, 140. *See also* Enterohemorrhagic *E. coli* enteritis; Enteropathogenic *E. coli* enteritis; Enterotoxigenic *E. coli*
- ETEC. *See* Enterotoxigenic *E. coli*
- Ethambutol, 148, 203, 237
- Evidence-based medicine (EBM), 1
 diagnosis in, 3
 etiology in, 3
 framing questions in, 3
 hierarchy in, 2–3
 prognosis in, 3
 searching literature in, 3–8
- Evidence-based practice, 1–8
- Extended spectrum betalactamase (ESBL), 9
- Extracorporeal membrane oxygenation (ECMO)
 in severe sepsis, 247
- Eye infections, 40–51
- Famciclovir, 44, 218, 291
- Familial Hibernian fever (FHF), 70
- Familial Mediterranean fever (FMF), 69–70
- Febrifuge, 264
- Febrile neutropenia, 117–125
 clinical features, 117
 duration of treatment, 120
 empiric antibiotic treatment of, 118–120
 laboratory markers of, 117–118
 organisms causing, 117
 outpatient management, 120
 persistent fever and, 120–124
 preventive therapy for, 124–125
 colony-stimulating factors to, 124–125
- Fever, 55–70
 acute phase reactants in, 59–60
 age and, 56–57
 chest radiograph in, 60
 clinical assessment of, 57
 comparative features of, 69*t*
 CSF in, 60
 defined, 55
 focus of infection in, 59
 height of, 56
 investigation of, 59–60
 management, 60–62
 antibiotics in, 60–61
 antipyretics in, 61–62
 recommendations, 62*b*
 management algorithm, 58*f*
 measuring, 55–56
 of unknown origin, 68
 physical reduction methods for, 62
 prolonged, 68
 neutropenia and, 120–124

Index

- Fever (*Cont.*)
- recurrent, 68–70
 - toxicity and, 57–58, 59*b*
 - urinalysis and urine culture in, 60
 - UTI and, 273
 - white blood count in, 59
 - with petechial rash, 62–63
 - with purpura, 62–63
- FHE. *See* Familial Hibernian fever
- Fine needle aspiration (FNA)
- for mycobacterial infection, 33
 - in cervical lymphadenopathy, 32
- Fluconazole, 121, 122, 123, 149, 192, 193, 214, 279
- Flucytosine, 20, 149, 193
- Fluid requirements, 75*t*, 76*b*
- Fluid therapy
- for malaria, 261–262
 - in severe sepsis, 244–245
- Flumethasone, 173
- FME. *See* Familial Mediterranean fever
- FNA. *See* Fine needle aspiration
- Folliculitis, 230
- Framycetin, 10, 45, 172, 173
- Furuncles, 226–228
- Fusidate sodium, 158
- Fusidic acid, 12
- Fusobacterium necrophorum*, 37
- Ganciclovir, 51, 284
- GAS infection. *See* Group A streptococcal
- Gastrointestinal infections, 74–95
- GBS. *See* Group B streptococcal
- GCS. *See* Glasgow Coma Score
- Gentamicin, 10, 17, 18, 19, 20, 21, 60, 91, 143, 144, 173, 186, 189, 190, 196, 197, 219, 237, 238, 275
- Giardia*, 82, 90
- Glandular fever, 179
- Glasgow Coma Score (GCS), 133
- Globe, infections of, 49–51
- Glycemic control, in severe sepsis, 246
- Glycopeptides, 21, 123–124
- Gonococcal ophthalmia neonatorum, 45–46
- Gramicidin, 172, 173
- Group A streptococcal (GAS) infection, 22, 24, 176
- antibiotics for, 177–178
 - rapid diagnosis of, 177
 - vulvovaginitis, 212
- Group B streptococcal (GBS) infection, 212
- Guillain-Barré syndrome, 150
- H. aegyptius*, 43
- H. influenzae*, 41, 137, 140, 157, 166, 172, 176, 178, 194, 195
- HAART. *See* Highly active antiretroviral therapy
- HACEK organisms, 15
- Head lice, 233
- Helicobacter pylori*, 91
- Hematology, in cervical lymphadenopathy, 32
- Hepatic hydatid cysts, 257
- Hepatitis A, 92
- Hepatitis B, 92–94
- babies born to mothers with, 93
 - immunization, 92–93
 - post-exposure prophylaxis, 93–94, 220
 - prevention of, 92–94
 - treatment of, 94
- Hepatitis C, 94
- Herpes simplex virus (HSV), 285–287
- conjunctivitis, 42, 44, 46
 - encephalitis, 145–146
 - genital infection, 218
 - gingivostomatitis, 286
 - in immunocompromised children, 287
 - neonatal, 285–286
 - prevention of, 286–287
 - recurrent, 286–287
- Highly active antiretroviral therapy (HAART), 102–103, 104–106
- combinations, 105–106
 - drug interactions, 105
 - in children, 106*t*
 - when to start, 104–105
- HIV infection, 29, 89–90, 102–113, 137, 216, 217, 225
- clinical presentation of, 102–103
 - diagnosis of, 103–104
 - IgG antibodies and, 103
 - IgM antibodies and, 104
 - immunization, 107
 - management issues, 107
 - MTCT and, 108–111
 - needlestick exposure to, 112
 - PCP prophylaxis in, 106–107
 - PCR and, 104
 - post-exposure prophylaxis, 111–113
 - prophylaxis, 220
 - sexual exposure to, 112
 - slow progressors, 102
 - tests for, 103*t*
 - transmission risks, 111
 - treating opportunistic infections in, 107
 - viral antigen, 103
 - viral culture, 103
 - web sites on, 113
- Hookworms, 95, 229
- HPV. *See* Human papillomavirus
- HSV. *See* Herpes simplex virus
- HSV encephalitis, 145–146
- Human papillomavirus (HPV), 218–219
- Hydatid disease, 257
- Hyperbaric oxygen, 233
- Hyperimmunoglobulin D (hyper-IgD) syndrome, 70

- Hybernemia, 75
 Hypertonic saline, for cystic fibrosis, 198
- IgG antibodies, 103–104
 Imipenem, 190
 Immune deficiency, 117–127
 Immune reconstitution syndrome (IRS), 102–103
 Immunization, 12
 asplenia, 126
 bites and, 225–226
 Immunofluorescent antibodies (IFA), 67, 283
 Impetigo, 230–231
 Infants, febrile, 56–57
 Infectious mononucleosis, 179
 Infective endocarditis, 14–22
 chemoprophylaxis for, 21–22, 23*t*
 clinical presentation of, 14
 complicated, 18
 diagnosis of, 15–16
 blood cultures, 15
 echocardiography, 15
 organisms causing, 14–15
 risk for, 22*t*
 treatment of, 16–21
 antimicrobials, 16–17
 blood parameters in, 21
 cat scratch, 19
 culture-negative, 20
 empiric, 17
 enterococcal, 18–19
 fungal, 20
 HACEK group, 19
 penicillin allergy and, 20
 prosthetic material, 19–20
 S. aureus, 19
 streptococcal, 17–18
 surgical, 16
 Influenza, 181
 Inotropes, 245–246
 Insecticide-treated bed nets, 262
 Interferon-gamma assays, and TB, 200
 Intermittent catheterization, 280
 Intracranial pressure (ICP), 133
 Intravenous immunoglobulin (IVIG), 66, 146, 150
 for necrotizing skin infections, 233
 in KD, 64
 in severe sepsis, 246
 Intravenous therapy (IVT), 77
 Iodoquinol, 89
 Iridocyclitis, 50
 Isoniazid, 34, 200, 201, 203
Isospora belli, 91
 Itraconazole, 122, 191, 214
 Ivermectin, 95, 230, 236
 IVIG. *See* Intravenous immunoglobulin
- Janeway lesions, 14
 Juvenile idiopathic arthritis (JIA), 70
- Kawasaki disease (KD), 63–64
 aspirin in, 65
 corticosteroids in, 65–66
 diagnostic criteria for, 64*b*
 echocardiography in, 64
 investigations in, 64*b*
 IVIG in, 64
 laboratory tests for, 63–64
 management of, 64
 in treatment-resistant children, 66
 KD. *See* Kawasaki disease
 Keratoconjunctivitis, 48
Kingella kingae, 157
Klebsiella, 49, 91, 160, 193
- Lactose-free formula, 80
 Lamivudine, 108, 220
 Lateral pharyngeal abscess, 36
Legionella, 20
 Lemierre syndrome, 37, 193
 Leukemia, 125
 Liposomal amphotericin, 121, 122
Listeria monocytogenes, 49, 134
 Liver abscesses, 91
 Lopinavir, 220
 Lower respiratory tract infections, 182–203
 Ludwig angina, 36–37
 Lumbar puncture (LP), 132–134
 delayed, 133–134
 Lumefantrine, 259, 264
 Lung abscess, 193
 Lyme disease, 67–68
 Lyme meningitis, 147
- MAC. *See* *Mycobacterium avium* complex
 Macrolide, 10, 197–198
 Magnetic resonance imaging (MRI)
 in acute osteomyelitis, 157
 Malaria, 257–264
 adjunctive therapy for, 260
 antimalarials for severe, 260
 chemoprophylaxis, 262–263
 recommendations on, 263
 chloroquine-resistant, 263–264
 emergency treatment of, 264
 fluid therapy for, 261–262
 prevention of, 262–264
 treatment of, 258–262
 Malassezia, 230
 Mastoiditis, 172–173
 acute, 172
 chronic-173, 172

Index

- McIsaac scoring system, 177b
- MDR organisms. *See* Multi-drug-resistant organisms
- Measles, 287–290
- immunization, 289
 - post-exposure prophylaxis, 289
 - prevention of, 289–290
 - treatment of, 287–289
 - antibiotics, 288–289
 - vitamin A, 287–288, 289–290
- Mebendazole, 95, 212
- Medline, 2, 6
- Mefloquine, 261, 264
- Meibomian abscess, 49
- Melioidosis, 264–265
- Meningitis, 132–151
- Meningococcal infection, 63
- antibiotic treatment of, 249–250
 - chemoprophylaxis for, 251
 - clinical diagnosis of, 248–249
 - corticosteroids in, 250–251
 - immunization, 251–252
 - management of, 248–252
- Meropenem, 119, 136, 141, 190, 232
- Meta-analysis, 2
- searching for, 6
- Methicillin-resistant *S. aureus* (MRSA), 189
- Metronidazole, 36, 37, 83, 89, 142, 143, 193, 214, 219, 220, 225, 238
- Microsporidium, 91
- Micturating cystourethrogram, 276
- Modified Duckett Jones criteria, 24
- Modified Duke criteria, 15–16
- simplified, 16b
- Monoclonal antibodies
- in meningococcal infection, 251
 - in systemic sepsis, 247
 - meningococcal infection in, 251
- Moraxella*, 47, 166, 178
- Mother-to-child-transmission (MTCT), 102, 106, 108–110
- Moxifloxacin, 137, 189, 265
- MRI. *See* Magnetic resonance imaging
- MRSA. *See* Methicillin-resistant *S. aureus*
- MTCT. *See* Mother-to-child-transmission
- Mucosal penetration, 10
- Multi-drug-resistant (MDR) organisms, 189
- Munchausen syndrome, 140
- Mupirocin, 230
- Mycobacterial infection, 32–33
- fine needle aspiration for, 33
 - non-tuberculous, 202–203
- Mycobacterium avium*, 29, 32
- Mycobacterium avium* complex (MAC), 202–203
- disseminated, 203
 - Mycobacterium kansasii*, 203
 - Mycobacterium marinum*, 236–237
 - Mycobacterium pneumoniae*, 193
 - Mycobacterium scrofulaceum*, 29, 32
 - Mycobacterium tuberculosis*, 32, 33, 103, 142, 193
- Mycoplasma meningoenzephalitis, 146
- Naloxone, in severe sepsis, 247
- Naproxen, 25
- Nasogastric tube feeds, 78
- National Health Service (NHS), 2
- Necator americanus*, 95, 229
- Necrotizing skin infections, 231–233
- antibiotics for, 232–233
 - clinical features of, 231–232
 - diagnosis of, 231–232
 - hyperbaric oxygen for, 233
 - IVIG for, 233
 - treatment of, 232–233
- Neisseria gonorrhoeae*, 20, 212–213, 215
- Neisseria meningitidis*, 49, 140
- Nelfinavir, 220
- Neomycin, 45
- Neonatal eye infections, 45–47
- Neonates
- bacterial meningitis in, 134–136
 - cervical lymphadenopathy and, 31
 - febrile, 56
 - HSV in, 285–286
- Neurocystercosis, 266
- Neurosyphilis, 218
- Nevirapine, 108
- NHS. *See* National Health Service
- Nitazoxanide, 90
- in acute gastroenteritis, 82
- Nitric oxide antagonists, 247
- Nitrofurantoin, 10, 278
- Nocardia*, 142
- Nocardiosis, 35
- Non-randomized studies
- searching for, 7
- Non-tuberculous mycobacterial infection, 202–203
- Non-typhoid *Salmonella* enteritis, 84–85
- Norfloxacin, 88, 215, 275
- Nucleic acid detection
- TB and, 200
- Nystatin, 214
- Obsessive compulsive disorder, 151
- Ofloxacin, 86
- OME. *See* Otitis media with effusion
- Open fractures, 162

- Opportunist infections, 107
- Oral feeds, 78
- Oral hydration therapy (ORT), 77
in acute gastroenteritis, 78
- ORT. *See* Oral hydration therapy
- Oseltamivir, 181
- Osler nodes, 14
- Osteomyelitis, 156–162
- Otitis externa, 173
- Otitis media with effusion (OME), 166
antibiotics in, 170
antihistamines for, 171
chronic, 169–171
corticosteroids, 170
decongestants for, 171
diagnosis, 169–170
ventilation tubes for, 170–171
- Oxacillin, 11, 19
- P. jiroveci*, 106–107, 190–191
corticosteroids for, 191
mild to moderate, 190
prophylaxis against, 126–127
severe, 190–191
- Palivizumab
for bronchiolitis, 184–185
- PANDAS, 150–151
- Papua New Guinea (PNG), 138
- Paratyphoid fevers, 85–86
- Paromomycin, 89
- Pasteurella multocida*, 224
- PCR. *See* Polymerase chain reaction
- Pediculosis capitis, 233
- Pelvic inflammatory disease, 219
- Penciclovir, 286
- Penicillin, 12
- Perianal cellulitis, 233–234
- Periocular cellulitis, 40–41
bacteremia-associated, 41
deep orbital, 40–41
local, 40
- Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome, 70
- Peritonsillar abscess, 36
- Permethrin, 25, 235, 236
- Pertussis, 181–182
prevention of, 182
prophylaxis against, 182
treatment of, 181–182
- Petechiae
fever with, 62–63
- PFAPA syndrome. *See* Periodic fever, aphthous stomatitis, pharyngitis, and adenitis syndrome
- Pharyngitis, 176–179
recurrent, 179–180
- Pharyngoconjunctival fever, 43
- Phenoxymethyl penicillin, 26, 178, 179, 211, 212, 226–228, 229, 231
- Physical therapy
for bronchiectasis, 195
for cystic fibrosis, 198
- Pinworms, 95, 211, 212, 233
- Piperacillin, 158, 162, 173, 190, 225, 237
- Plasmapheresis, 146, 147
- Plasmodium falciparum*, 258–259, 260
- Pleural empyema, 193–194
antibiotic treatment of, 194
diagnosis of, 194
operative therapy for, 194–195
- Pneumonia, 185–193
aspiration, 193
Candida, 192
community-acquired, 185–187
antibiotic treatment of, 186–187
investigations of, 186
Cryptococcus, 192–193
diagnosis, 185
fungal, 191–193
hospital-acquired, 188–190
in immunocompromised child, 190
staphylococcal, 188
- PNG. *See* Papua New Guinea
- Polymerase chain reaction (PCR), 212, 283
CSF testing, 144–145
HIV and, 104
in cervical lymphadenopathy, 33
on CSF, 134
- Polymyxin, 45
- Post-sexual assault prophylaxis, 219–220
antibiotic, 220
HBV, 220
HIV, 220
- Praziquantel, 266
- Prednisolone, 149, 170, 180
- Prednisone, 180
- Pregnancy
in TB, 202
syphilis and, 216–217
- Primaquine, 262
- Probiotics
in acute gastroenteritis, 81–82
- Procaine penicillin, 217, 225, 229
- Prognosis
evidence about, 3
- Proguanil, 264
- Propionibacterium*, 141

Index

- Protozoal infections, 88–91
Pseudomonas aeruginosa, 10, 20, 46–47, 49, 118–119, 158, 195, 230
 exacerbations of, 197
 initial colonization, 196
Pseudomonas fluorescens, 224
 PubMed, 2, 6, 7
 clinical queries page, 6*f*
 home page, 5*f*
 Pulmonary hydatid disease, 257
 Purpura
 fever with, 62–63
 Purulent rhinitis, 173–175
 Pyelonephritis, 274
 antibiotics for, 275–276
 Pyomyositis, 234
 Pyrantel, 95, 212
 Pyrazinamide, 34, 148, 201
 Pyrimethamine, 51
- Q fever, 265
 Quinine, 259
 Quinolone, 10
- Radionuclide scans, 157
 Rapid IV rehydration, 77
 RCT, 1, 2, 21, 25, 43
 Recurrent eyelid swelling, 41
 Recurrent furuncles, 227–228
 Red Book, 199
 Rehydration
 in acute gastroenteritis, 75–77
 rapid IV, 77
 Respiratory tract infections, 162–203
 Retropharyngeal abscess, 36
 RhDNase, for cystic fibrosis, 198
 Ribavirin
 for bronchiolitis, 183
 for hepatitis C, 94
 Rifabutin, 203
 Rifampicin, 12, 19, 34, 105, 139, 148, 158, 188, 201, 203, 228, 237, 251, 256
 Rifampin, 139, 158, 203
 Rifaximin, 88
 Ritonavir, 220
 Rochester criteria, 57*b*
 Roundworms, 229
 Roxithromycin, 12, 178, 187, 215
 RSV immunoglobulin, for bronchiolitis, 184
- S. agalactiae*, 134
S. anginosus, 142
S. haematobium, 265, 266
S. japonicum, 266
S. mansoni, 266
S. milleri, 193
S. pyrogenes, 26, 172, 176, 178, 194, 211, 230
Saccharomyces boulardii, 81
Salmonella, 160
Sarcoptes scabiei, 234
 SARS. *See* Severe acute respiratory syndrome
 Scabies, 234–236
 crusted, 236
 in babies, 235
 oral treatment for, 235–236
 topical treatment for, 235
Scedosporium, 142
 Schistosomiasis, 265–266
 Searching
 Cochrane reviews, 3–5
 for diagnosis queries, 7–8
 for meta-analysis, 6
 for non-randomized studies, 7
 for RCTs, 7
 question type in, 7*t*
 systematic reviews, 5–6
 Sepsis bundles, 247–248
 Sepsis, severe
 activated protein C, 247
 antibiotics, 243–244
 colony-stimulating factors, 247
 ECMO, 247
 fluid therapy, 244–245
 glycemic control, 246
 IVIG, 246
 naloxone, 247
 nitric oxide antagonists, 247
 Septic arthritis, 161–162
 Septic shock, 245–246
 Serology, 283
 Severe acute respiratory (SARS), 198
 Severe sepsis. *See* sepsis, severe
 Sexual abuse, 212
 Sexually transmitted infections, 211–220
 post-sexual assault prophylaxis for, 219–220
 Shigellosis, 86
 Shingles, 290–294
 SIADH. *See* Syndrome of inappropriate antidiuretic hormone secretion
 Sinusitis, 175–176
 Skin infections, 224–238
 Skin sepsis, 24–25
 Skull fracture, and bacterial meningitis, 139–140
 Soft tissue infections, 224–238
 Sore throat, 24
 antibiotics for, 177
 McIsaac scoring system for, 177*b*
 SPA. *See* Suprapubic aspiration

- Spinal epidural abscess, 143–144
- Splenectomy, 125–126
- Splenomegaly, 14
- Staphylococcal toxic shock syndrome, 252
- Staphylococcus aureus*, 9, 14, 15, 49, 62, 91, 141, 157, 160, 172, 193, 194, 224, 230, 233, 234, 288
- endocarditis, 19
 - methicillin-resistant, 189
 - methicillin-sensitive, 227–228
 - neonatal conjunctivitis from, 46–47
- Streptococcal tonsillopharyngitis, 177
- Streptococcal toxic shock syndrome, 252
- Streptococci
- in infective endocarditis, 17–18
 - benzylpenicillin-resistance, 18
- Streptococcus pneumoniae*, 10, 11, 29, 41, 47, 59, 62, 125, 134, 166, 172, 195
- Streptococcus viridans*, 288
- Strongyloides stercoralis*, 95
- Strongyloidiasis, 95
- Stye, 49
- Subdural empyema, 142
- Sulbactam, 225
- Sulfadiazine, 51
- Sulfur, 235
- Suprapubic aspiration (SPA), 272
- Syndrome of inappropriate antidiuretic hormone secretion (SIADH), 79
- Syphilis, 215–218
- early, 217
 - late latent, 217–218
 - pregnancy and, 216–217
 - tertiary, 218
 - treatment of, 216
- Systematic reviews, 2, 5–6
- Systemic sepsis, 243–252
- activated protein C in, 247
 - antibiotic therapy for, 243–244
 - colony stimulating factors, 247
 - ECMO in, 247
 - fluid therapy in, 244–245
 - glycemic control, 246
 - goal-directed therapy in, 247
 - IVIG in, 246
 - management of, 248
 - monoclonal antibodies in, 247
 - naloxone in, 247
 - nitric oxide antagonists in, 247
- Tapeworm, 95
- Tazobactam, 162, 173, 190
- TB. *See* Tuberculosis
- TBM. *See* Tuberculosis meningitis
- Teicoplanin, 21
- Thiabendazole, 230
- Threadworms, 95, 212
- Ticarcillin, 162, 173, 189, 190, 225, 237
- Tinidazole, 89, 90, 91, 214, 220
- TMP-SMX. *See* Trimethoprim-sulfamethoxazole
- TNF. *See* Tumor necrosis factor
- Tobramycin, 196, 197
- Tourette syndrome, 151
- Toxicity
- in febrile children, 57, 59*b*
- Toxoplasma chorioretinitis, 51
- Toxoplasma gondii*, 51, 142
- Trachoma, 47–48
- Transverse myelitis, 149–150
- Traveler's diarrhea, 86–88
- prevention of, 87
 - treatment of, 87–88
- Treatment, clinical questions about, 4*f*
- Treponema pallidum*, 216
- Trichuris trichiura*, 95
- Trimethoprim, 215, 275
- Trimethoprim-sulfamethoxazole, 10, 51, 86, 88, 127, 191, 265
- Trimethoprim-sulfamethoxazole (TMP-SMX), 106–107, 127, 256
- Tropical infections, 256–266
- TST. *See* Tuberculin skin testing
- Tuberculin skin testing (TST), 32–33, 199
- Tuberculosis (TB), 102, 198–202
- corticosteroids and, 202
 - diagnosis, 199
 - DOT, 202
 - extrapulmonary, 201–202
 - in breast-feeding, 202
 - in pregnancy, 202
 - interferon-gamma assays and, 200
 - nucleic acid detection, 200
 - prevention of, 202
 - treatment of, 200–202
 - TST and, 199
- Tuberculosis meningitis (TBM), 147–149
- clinical presentation of, 147
 - diagnosis of, 147–148
 - treatment of, 148–149
 - corticosteroids in, 148–149
- Tumor necrosis factor (TNF), 70
- Tympanocentesis, 166
- Tympanometry, 166
- Typhoid fevers, 85–86
- Ultrasound
- abdominal, for prolonged fever, 68
 - in acute osteomyelitis, 156
 - in cellulitis, 229
 - in epididymo-orchitis, 214–215

Index

- Ultrasound (*Cont.*)
 in hepatic hydatid cysts, 257
 in UTI, 276–277
 Upper respiratory tract infections (URTIs), 10, 11, 166–182
 Urinalysis
 in acute epididymo-orchitis, 215
 in fever, 60
 in UTI, 60, 272–273
 Urinary tract infection (UTI), 271–279
 aminoglycosides and, 275
 antibiotic treatment for, 273–284
 catheter-associated, 279–280
 definition of, 271
 fever and, 273
 imaging following, 276–277
 preventing, 277–279
 prophylactic antibiotics, 278–279
 urinalysis for, 272–273
 urine in, 272
 URTIs. *See* Upper respiratory tract infections
 UTI. *See* Urinary tract infection
 Uveitis, 50

 Valaciclovir, 44, 218, 291
 Valganciclovir, 51
 Vancomycin, 11, 18, 19, 20, 21, 50, 83, 134, 136, 137, 141,
 142, 144, 172, 188, 190, 194, 229, 234, 237, 238, 243,
 252
 Varicella zoster immune globulin (VZIG), 292, 293–294
 Varicella zoster virus (VZV), 230, 290–294
 antiviral treatment of, 290
 immunization, 291–292
 ophthalmic, 43
 post-exposure immunization, 292
 prevention, 291–294
 Vasopressors, 245–246
 Vector avoidance, 262
 Ventilation tubes, for chronic OME, 170–171
 Viral culture, 283
 Viral encephalitis, 145

 Viral infections, 283–294
 diagnosing, 283
 Viral meningitis, 144–145
 clinical features of, 144
 CSF microscopy, 144
 CSF-PCR testing in, 144–145
 serology, 145
 treatment of, 145
 viral culture in, 145
 Vitamin A, 289–290
 in gastroenteritis, 81
 measles and, 287–288, 289–290
 Vitamin C
 common cold and, 174
 Voriconazole, 121, 123, 192
 Vulvovaginal candidiasis, 213–214
 Vulvovaginitis, 211–214
 enterobius and, 212
 foreign bodies and, 212
 GAS, 212
 GBS, 212
 non-specific, 211–212
 trichomonas, 214
 VZIG. *See* Varicella zoster immune globulin
 VZV. *See* Varicella zoster virus

 Water-related infections, 236–237
 Whipworm, 95
 White blood count, 58, 59
 Worms, 95, 211, 212, 229, 233
 Wound infections, 237–238
 clean, 238
 contaminated, 238
 post-traumatic, 238

 Zanamivir, 181
 Zidovudine, 108, 109
 ZIG. *See* Zoster immune globulin
 Zinc, 81, 174–175
 Zoster immune globulin (ZIG), 292, 293*b*